QPPV.COM KNOWLEDGE ASSESSMENT

EU Pharmacovigilance Inspection Findings: Cross-Functional and Interface Controls

Test your understanding of the concepts covered by EU Pharmacovigilance Inspection Findings: Cross-Functional and Interface Controls.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is a technically functioning EudraVigilance gateway not, by itself, sufficient evidence of an effective PV-EudraVigilance interface?

Because electronic submissions are prohibited for MAHs Because rejected messages, acknowledgements, reconciliation exceptions and configuration changes also require operational control Because all submissions must be reviewed by the competent authority before transmission Because gateway performance is relevant only to IT and not pharmacovigilance

Question 2 of 10 When reviewing a safety-related regulatory communication, which sequence best reflects an effective interface control?

Archive the communication, then determine later whether it had safety implications Recognise the safety relevance, route it appropriately, assess implications, involve relevant PV governance and track resulting actions Send it to the legal department because regulatory correspondence is not a PV matter Forward it to PV without recording receipt or documenting the subsequent assessment

Question 3 of 10 Which root-cause analysis is strongest for a delayed medical-information-to-PV transfer?

The employee made a human error, so retraining is sufficient Communication was poor, with no further analysis required The organisation should examine recognition criteria, queue monitoring, timestamps, transfer controls, reconciliation and escalation The delay is irrelevant if the report was eventually entered into the PV database

Question 4 of 10 An MAH outsources literature screening to a service provider. Which interpretation is most consistent with the EU pharmacovigilance framework described in the article?

The vendor assumes the MAH's ultimate responsibility once the contract is signed The QPPV becomes responsible for performing all outsourced operational tasks personally The MAH may delegate activities but retains ultimate responsibility for its pharmacovigilance system The competent authority becomes responsible for monitoring the vendor's daily performance

Question 5 of 10 During a major database migration, which approach best addresses interface risk?

Treat the migration solely as an IT project because the PV process remains unchanged in principle Assess which recipients, decision points, authoritative systems and information flows may change, and control the transition Suspend all PV oversight until the new system is fully operational Rely on the previous system's procedures without reassessing them

Question 6 of 10 Which question is most useful when evaluating whether a receiving function can act effectively after a hand-off?

Was the sending function's SOP formatted according to the corporate template? Did the receiving function receive complete and usable information within the applicable timeframe? Did the sender and recipient attend the same training session? Was the transfer made by email rather than by a system?

Question 7 of 10 Which combination best represents the three dimensions that an effective interface control should address?

Training, auditing and inspection readiness Information, responsibility and control Products, countries and legal entities Detection, assessment and submission

Question 8 of 10 Why can exception cases be particularly valuable when sampling an interface?

They are the only transactions that can be used for regulatory decisions They reveal whether the control can detect, contain and correct deviations from the normal workflow They eliminate the need to sample successful transactions They demonstrate that the normal process is invalid

Question 9 of 10 A safety database outage is managed by IT as a technical incident. What should determine whether it also requires pharmacovigilance assessment?

Whether the incident lasted more than one business day Whether the incident could affect case entry, assessment, submission or reporting timelines Whether the QPPV personally opened the IT ticket Whether the database vendor caused the outage

Question 10 of 10 What is the main inspection concern when safety information can arise in clinical or development functions?

Development functions must be eliminated from the pharmacovigilance system Safety information may remain trapped in a functional silo instead of reaching the appropriate PV process All development data must be submitted as individual case safety reports Clinical staff must replace the QPPV for development-related information

EU Pharmacovigilance Inspection Findings: Cross-Functional and Interface Controls

Cookie Settings